2001
DOI: 10.1016/s0167-0115(00)00167-1
|View full text |Cite
|
Sign up to set email alerts
|

Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
17
0

Year Published

2004
2004
2018
2018

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 34 publications
(17 citation statements)
references
References 24 publications
0
17
0
Order By: Relevance
“…25 Our group previously found that decreased pancreastatin levels after TACE treatment may correlate with response to treatment, and proposed that an increase in pancreastatin level after a previous decrease may provide an indication for repeat TACE. 13 Seventy-eight percent of patients treated with TACE experienced decreased or stable levels of pancreastatin after treatment; those whose pancreastatin levels did not decrease at least 20% after treatment all died within 8 months. 13 The fact that pancreastatin response to TACE treatment was not able to predict survival in the present group of patients may be caused by the relatively small number of patients in this study.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…25 Our group previously found that decreased pancreastatin levels after TACE treatment may correlate with response to treatment, and proposed that an increase in pancreastatin level after a previous decrease may provide an indication for repeat TACE. 13 Seventy-eight percent of patients treated with TACE experienced decreased or stable levels of pancreastatin after treatment; those whose pancreastatin levels did not decrease at least 20% after treatment all died within 8 months. 13 The fact that pancreastatin response to TACE treatment was not able to predict survival in the present group of patients may be caused by the relatively small number of patients in this study.…”
Section: Discussionmentioning
confidence: 96%
“…Finally, biochemical response to therapy was determined by assessment of serum pancreastatin levels. 13 …”
Section: Assessment Of Responsementioning
confidence: 99%
“…[22][23][24][25] Previously, we showed that a 20% reduction in serum pancreastatin correlated with improved outcome after HACE for carcinoid. 9 Using this same cutoff, responses were seen in 80% of patients including complete response in 14%. This response correlated with other measures of response as well as being predictive of improved survival by univariate analysis.…”
Section: Discussionmentioning
confidence: 99%
“…Complete response was considered as normalization (i.e., <135 pg/ml) of serum pancreastatin in a patient who had an elevated pancreastatin before HACE. A reduction of pancreastatin by 20% or more was considered a partial response, 9 whereas an initial increase by 20% or more was considered a progression. Stable disease was defined as an increase or decrease in pancreastatin by less than 20%.…”
Section: Response Assessmentmentioning
confidence: 99%
“…31 However, no study to date has demonstrated the potential survival benefit of the known biochemical response with somatostatin therapy.…”
Section: Discussionmentioning
confidence: 99%